Evidence map›Paper›PMID 34873551›Full record

ArticleCureus2021

Induced Native Phage Therapy for the Treatment of Lyme Disease and Relapsing Fever: A Retrospective Review of First 14 Months in One Clinic.

David A Jernigan, Martin C Hart, Keeley K Dodd, Samuel Jameson, Todd Farney

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Optimising Transformation Efficiency inInternational journal of molecular sciences · 2024
    Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

David A JerniganBiological Medicine, Biologix Center for Optimum Health, Franklin, USA.
Martin C HartBiological Medicine, Biologix Center for Optimum Health, Franklin, USA.
Keeley K DoddResearch and Development, PhagenCorp, LLC, Sarasota, USA.
Samuel JamesonBiological Medicine, Biologix Center for Optimum Health, Franklin, USA.
Todd FarneyBiological Medicine, Biologix Center for Optimum Health, Franklin, USA.
Optimum Therapeutics (United States) · USLabCorp (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The overall failure rate of standard therapeutic options for late/chronic/persistent borreliosis emphasizes the need for novel therapeutic strategies. In this report, we are presenting a novel therapeutic option based on a new technology, Induced Native Phage Therapy (INPT; PhagenCorp, LLC, Sarasota, FL), and its ability to facilitate the elimination of infection more rapidly, efficiently, and with less harm to the patient than conventional treatments.

Indexed as

bacteriophage therapyborreliachronic lyme diseaseherxheimer reactioninduced native phage therapy (inpt)inducen-ld/rfpost-treatment lyme disease syndrome (ptlds)relapsing fever

Identifiers

PMID34873551
PMCPMC8636187
OpenAlexW3216027223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.